RAP-219

Product

Last mentioned: Mar 10, 2026

Stories mentioning RAP-219 2

pharma Neutral

Biotech Earnings: Tenax, ADC, and Rapport Chart Paths for 2026 Growth

Three distinct biotech players—Tenax, ADC Therapeutics, and Rapport—released 2025 year-end results, highlighting a shift from foundational clinical trials to commercial scaling and late-stage readouts. While Tenax advances its Phase 3 LEVEL trial, ADC Therapeutics focuses on ZYNLONTA’s market penetration and Rapport prepares for key data in epilepsy.

3 sources
funding Neutral

Biotech Sector Outlook: Tenax, ADC, and Rapport Report FY2025 Results

Tenax Therapeutics, ADC Therapeutics, and Rapport Therapeutics reported their full-year 2025 financial results on March 10, 2026, highlighting a period of clinical execution and capital management. The updates underscore the diverging paths of commercial-stage ADC platforms and late-stage cardiovascular and neuroscience pipelines as they navigate the 2026 regulatory landscape.

3 sources